Enhanced Selective Inhibitors of Exon 20 Insertion Mutant EGFR for Cancer Treatment

This inventive concept presents a series of improvements and enhancements to the original selective inhibitor of exon 20 insertion mutant EGFR, offering targeted delivery, reduced systemic toxicity, and improved bioavailability for more effective cancer treatment.

The original patent disclosed a method for treating malignant lung tumors using a selective inhibitor of exon 20 insertion mutant EGFR. However, the original patent had limitations in terms of systemic toxicity and bioavailability. This new inventive concept addresses these limitations by introducing targeted delivery systems, improved formulations, and enhanced detection methods.

The new claims introduce a system for treating EGFR-related cancers, comprising a selective inhibitor of exon 20 insertion mutant EGFR formulated for targeted delivery to tumor cells with reduced systemic toxicity. Additionally, a method for identifying patients likely to respond to EGFR-targeted therapy is disclosed, which involves detecting the presence of exon 20 insertion mutations in EGFR and selecting patients with such mutations for treatment. Furthermore, a pharmaceutical composition with enhanced bioavailability and a kit for diagnosing EGFR-related cancers are also presented.

The new claims introduce the concept of targeted delivery and improved formulations, which are not obvious from the original patent. The inventive step lies in the combination of the selective inhibitor with targeted delivery systems and improved formulations, resulting in reduced systemic toxicity and improved bioavailability.

Alternative embodiments of the inventive concept could include using different types of targeted delivery systems, such as nanoparticles or liposomes, or combining the selective inhibitor with other anti-cancer agents. Variations of the pharmaceutical composition could include different carrier molecules or excipients to further enhance bioavailability.

The enhanced selective inhibitors of exon 20 insertion mutant EGFR have significant commercial potential in the cancer treatment market, particularly in the area of non-small cell lung cancer (NSCLC). The targeted delivery system and improved formulations could provide a competitive advantage in the market, and the diagnostic kit could also generate revenue through sales to research institutions and hospitals.